Epling, Gerald A. – Trademark Portfolio
Entity Type: 01
Epling, Gerald A. has 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Notable registered marks include MINDJAVA. The portfolio includes 1 registered trademark. Filings span 4 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 42 (Computer & Scientific). This trademark owner is based in Las Vegas, NV.
2251 N Rampart Blvd #245
Las Vegas, NV 89128
Showing of trademarks Trademarks
Trademark Classifications
Epling, Gerald A.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does Epling, Gerald A. have?
Epling, Gerald A. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 3 cancelled.
What trademark classes does Epling, Gerald A. file in?
Epling, Gerald A. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Epling, Gerald A.'s most well-known trademarks?
Epling, Gerald A.'s registered trademark portfolio includes well-known marks such as MINDJAVA. These are among 1 currently registered trademark in the portfolio.
What is Epling, Gerald A.'s trademark registration success rate?
Epling, Gerald A. has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.